Localized Alpha Therapy for Peritoneal Metastases Draws Strategic Focus at XDC 2026

According to a recent LinkedIn post from C Ray Therapeutics, the company is emphasizing emerging interest in localized alpha radiation therapies for treating peritoneal metastases in ovarian and gastrointestinal cancers. The post highlights the limitations of systemic chemotherapy and intravenous radioligand therapies in reaching micrometastases within the peritoneal cavity and frames drug-delivery geometry as a central challenge.

The post also notes that C Ray Therapeutics is co-organizing the International RDC Sub-Forum at the XDC Conference 2026 in Chengdu, where Oncoinvent CEO Oystein Soug is expected to lead a session on Ra-224 based localized alpha therapy. This focus on regional, receptor-independent radiopharmaceutical approaches suggests a potential strategic interest in technologies that target surface-level micrometastases while sparing critical organs.

For investors, the emphasis on Ra-224 platforms and localized retention within the peritoneal cavity points to a niche but high-need oncology segment where novel delivery formats could command premium pricing if clinically successful. The post further implies that scalable, GMP-compliant manufacturing of localized alpha therapies may become an important capability for contract development and manufacturing organizations, potentially positioning C Ray Therapeutics within a broader ecosystem play in advanced radiopharmaceutical production.

If the company can leverage its role in convening stakeholders at XDC 2026 to deepen partnerships or access enabling technologies, it could enhance its standing in the radiopharmaceutical value chain. However, the content remains focused on scientific and strategic themes rather than concrete pipeline milestones or commercial timelines, so the direct near-term financial impact is difficult to gauge from this communication alone.